As GxP and regulatory compliance specialists at Quality Systems Now, we support therapeutic goods manufacturers, testing laboratories, and biotechnology companies in navigating the evolving regulatory landscape in Australia. The Therapeutic Goods Administration (TGA) has published its Compliance Principles for 2026 and 2027, which outline the agency’s approach to monitoring, enforcing, and supporting compliance with the Therapeutic Goods Act 1989. These principles are designed to protect public health while providing regulated entities with a clear, risk-based framework for meeting their obligations.

The TGA’s approach for 2026–2027 builds on lessons learned from previous compliance periods, aligning regulatory priorities with emerging risks and industry developments. The framework focuses on five core compliance principles that guide TGA activities across import, export, manufacture, supply, and advertising of therapeutic goods. These principles are supplemented by quarterly-reviewed priority focus areas, ensuring that compliance efforts remain targeted and relevant to current public health risks.

Principle 1: Risk-Based Compliance Oversight

The first principle emphasises a risk-based approach to regulatory oversight. The TGA prioritises resources toward products, processes, or entities that pose the greatest potential risk to public health. High-risk products, such as new biologics, high-volume medicines, or complex medical devices, are subject to enhanced scrutiny, whereas lower-risk items are monitored proportionally. This targeted approach enables efficient use of regulatory resources while maintaining safety standards.

For regulated organisations, this principle requires maintaining comprehensive risk assessments, quality control measures, and mitigation strategies. Entities should identify critical control points in manufacturing, testing, and distribution, and implement corrective and preventative actions to reduce the likelihood of non-compliance. Documented evidence of these controls and risk management processes is essential for demonstrating adherence to GxP standards during inspections or audits.

Principle 2: Proactive Engagement with Industry

The TGA recognises that early and proactive engagement with industry improves compliance outcomes. Clear communication and guidance reduce the likelihood of inadvertent non-compliance. This principle encourages manufacturers, laboratories, and biotechnology companies to seek clarification on regulatory requirements, participate in consultations, and adopt best practices aligned with TGA expectations.

Proactive engagement enables early identification and resolution of potential compliance issues, decreasing the risk of regulatory sanctions. It also facilitates knowledge transfer and industry education, which supports continuous improvement and aligns operational practices with evolving regulatory requirements.

Principle 3: Transparency and Predictability

Transparency and predictability are critical components of effective regulation. The TGA aims to provide clear, consistent guidance and to apply enforcement measures in a predictable manner. Regulatory decisions, inspections, and enforcement actions are communicated in a manner that supports industry understanding and compliance.

Organisations can align with this principle by maintaining clear standard operating procedures, comprehensive documentation, and audit-ready records. Predictable and transparent processes enable companies to demonstrate compliance, facilitate regulatory inspections, and reinforce a culture of accountability and continuous quality improvement.

Principle 4: Accountability and Responsiveness

The fourth principle highlights accountability and responsiveness. Regulated entities are expected to take ownership of compliance obligations and respond promptly to identified issues. This includes reporting incidents, deviations, or breaches in accordance with TGA requirements and implementing corrective actions efficiently.

Developing robust incident management systems, monitoring deviations, and training personnel in regulatory responsibilities are essential for meeting this principle. Accountability demonstrates organisational commitment to public safety and can mitigate regulatory risk by evidencing proactive management of potential non-compliance.

Principle 5: Consistent Enforcement

The fifth principle ensures that enforcement actions are applied consistently across all regulated entities. Consistency enhances fairness, strengthens public trust, and maintains the integrity of the regulatory system. Enforcement measures can range from educational interventions to formal sanctions, depending on the severity and risk associated with non-compliance.

For organisations, understanding the spectrum of potential enforcement actions reinforces the importance of internal compliance programs, quality management systems, and routine audits. Consistent adherence to regulatory expectations minimizes risk of penalties and supports sustainable operations.

Priority Focus Areas

To operationalise these principles, the TGA identifies quarterly-reviewed priority focus areas. These areas reflect current risks to public health and safety and are informed by regulatory intelligence, inspection data, and emerging industry trends. Key areas include high-risk products, supply chain integrity, laboratory testing accuracy, manufacturing compliance, and advertising standards.

Regulated entities should continually monitor operations against these focus areas, ensuring risk mitigation strategies, quality systems, and compliance programs remain effective and current. This dynamic approach ensures that TGA compliance activities are aligned with the most pressing public health concerns and that organisations maintain ongoing readiness for inspection and audit.

Implications for Therapeutic Goods Organisations

Adherence to the TGA Compliance Principles 2026 and 2027 is essential for all stakeholders in the therapeutic goods sector. Manufacturers, laboratories, and biotechnology companies must evaluate and reinforce internal systems, implement robust quality and compliance programs, and ensure personnel are trained to meet regulatory expectations. By aligning with these principles, organisations reduce the likelihood of enforcement actions, enhance operational efficiency, and demonstrate a commitment to public safety.

Quality Systems Now supports organisations in navigating these compliance obligations, providing expertise in GxP systems, regulatory audits, risk assessments, and training programs. Our services help ensure that therapeutic goods operations meet TGA expectations and sustain compliance through systematic, science-based approaches.

Conclusion

The TGA Compliance Principles 2026 and 2027 provide a structured, risk-based framework for monitoring, enforcing, and supporting compliance with the Therapeutic Goods Act 1989. By implementing risk-based oversight, engaging proactively with regulators, maintaining transparency, demonstrating accountability, and ensuring readiness for consistent enforcement, organisations can effectively manage compliance obligations.

Therapeutic goods manufacturers, testing laboratories, and biotechnology companies benefit from aligning operations with these principles through improved quality systems, risk management, and regulatory preparedness. Quality Systems Now provides the expertise required to implement these principles effectively, helping organisations meet regulatory expectations, protect public health, and sustain operational excellence in Australia’s highly regulated therapeutic goods sector.